Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.

	Dec '20	Dec '21	Dec '22	Dec '23
account payables	1.21M -	1.03M 15.25%	1.31M 27.43%	1.00M 23.59%
accumulated other comprehensive income loss		-164K -	-692K 321.95%	-78K 88.73%
cash and cash equivalents	55.32M -	66.35M 19.94%	10.78M 83.76%	14.33M 33.00%
cash and short term investments	55.32M -	106.72M 92.94%	67.59M 36.67%	48.50M 28.25%
common stock		1K -	1K 0%	2K 100%
deferred revenue		3.74M -		-475K -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt		185K -	382K 106.49%
long term investments
net debt	-55.32M -	-65.82M 18.99%	-10.04M 84.75%	-13.86M 38.08%
net receivables
other assets
other current assets	46K -	1.66M 3,506.52%	2.25M 35.56%	1.72M 23.39%
other current liabilities	1.92M -	339K 82.36%	7.10M 1,993.22%	8.77M 23.63%
other liabilities
other non current assets		33K -	33K 0%
other non current liabilities
othertotal stockholders equity	11.71M -	36.73M 213.73%	148.30M 303.75%	181.56M 22.43%
preferred stock	55.80M -	108.95M 95.27%
property plant equipment net		535K -	745K 39.25%	476K 36.11%
retained earnings	-14.40M -	-42.20M 193.03%	-86.14M 104.14%	-140.56M 63.18%
short term debt		339K -	358K 5.60%	475K 32.68%
short term investments		40.38M -	56.81M 40.70%	34.17M 39.86%
tax assets
tax payables			34K -	40K 17.65%
total assets	56.24M -	108.95M 93.73%	70.62M 35.19%	50.70M 28.21%
total current assets	55.36M -	108.38M 95.77%	69.84M 35.56%	50.22M 28.09%
total current liabilities	3.13M -	5.44M 73.65%	8.76M 60.98%	9.77M 11.52%
total debt		524K -	740K 41.22%	475K 35.81%
total investments		40.38M -	56.81M 40.70%	34.17M 39.86%
total liabilities	3.13M -	5.63M 79.55%	9.15M 62.48%	9.77M 6.87%
total liabilities and stockholders equity	56.24M -	108.95M 93.73%	70.62M 35.19%	50.70M 28.21%
total non current assets	876K -	568K 35.16%	778K 36.97%	476K 38.82%
total non current liabilities		185K -	382K 106.49%
total stockholders equity	53.10M -	103.32M 94.57%	61.47M 40.51%	40.92M 33.43%

COM:LONGBOARDPHARMA

Longboard Pharmaceuticals

Last Close

59.77

22/11 21:00

Market Cap

1.44B

Beta: -

Volume Today

1.29M

Avg: -

Preview